
Lannett Company LCI
Quarterly report 2023-Q1
added 05-15-2023
Lannett Company EV - Enterprise Value 2011-2026 | LCI
Annual EV - Enterprise Value Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 648 M | 657 M | 921 M | 977 M | 1.33 B | 1.69 B | 2.12 B | 1.97 B | 1.18 B | 391 M | 163 M | 164 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.12 B | 163 M | 1.02 B |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.11 | 4.25 % | $ 119 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
23.6 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Evolus
EOLS
|
467 M | $ 5.61 | 35.71 % | $ 362 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.66 | 2.31 % | $ 1.39 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 39.84 | 3.2 % | $ 1.46 B | ||
|
Jupiter Wellness
JUPW
|
91.9 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
11.1 M | $ 0.58 | 4.82 % | $ 10.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.93 | -14.3 % | $ 55.3 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
-110 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.67 | 5.46 % | $ 86.3 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.96 | 2.96 % | $ 390 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.93 | 0.17 % | $ 457 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
141 M | $ 12.19 | 2.44 % | $ 866 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.65 | -1.4 % | $ 2.06 B | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.41 | 3.2 % | $ 402 M | ||
|
Perrigo Company plc
PRGO
|
7.03 B | $ 11.63 | 2.15 % | $ 1.61 B | ||
|
Rockwell Medical
RMTI
|
57.3 M | $ 0.9 | 0.44 % | $ 21 M | ||
|
Sundial Growers
SNDL
|
-2.47 M | $ 1.56 | 1.63 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
33.6 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 22.89 | 3.57 % | $ 1.06 B | ||
|
Veru
VERU
|
111 M | $ 2.6 | 3.17 % | $ 351 M | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
Viatris
VTRS
|
41.3 B | $ 14.81 | -0.57 % | $ 17.8 B | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.74 | -3.77 % | $ 3.19 M | ||
|
Relmada Therapeutics
RLMD
|
170 M | $ 4.76 | 2.03 % | $ 143 M | ||
|
SCYNEXIS
SCYX
|
91.7 M | $ 0.76 | 0.96 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
197 M | $ 6.26 | 5.03 % | $ 256 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.96 B | $ 7.45 | 1.22 % | $ 4.6 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M |